Frazer IH. 2009. Interaction of human papillomaviruses with the host immune system: A well evolved relationship. Virology 384:410–414.

Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, Schiller JT, Gonzalez P, Dubin G, Porras C, Jimenez SE, Lowy DR, Costa Rican HPV Vaccine Trial Group. 2007. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: A randomized trial. JAMA 298:743–753.

Ho GY, Studentsov Y, Hall CB, Bierman R, Beardsley L, Lempa M, Burk RD. 2002. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis 186:737–742.

Holowaty P, Miller AB, Rohan T, To T. 1999. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 91:252–258.

Kadish AS, Ho GY, Burk RD, Wang Y, Romney SL, Ledwidge R, Angeletti RH. 1997. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: Outcome of HPV infection and associated neoplasia. J Natl Cancer Inst 89:1285–1293.

Kawana K, Yasugi T, Kanda T, Kawana Y, Hirai Y, Yoshikawa H, Taketani Y. 2002. Neutralizing antibodies against oncogenic human papillomavirus as a possible determinant of the fate of low-grade cervical intraepithelial neoplasia. Biochem Biophys Res Commun 296:102–105.

Kirnbauer R, Chandrachud LM, O'Neil BW, Wagner ER, Grindlay GJ, Armstrong A, McGarvie GM, Schiller JT, Lowy DR, Campo MS. 1996. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 219:37–44.

Kondo K, Ishii Y, Ochi H, Matsumoto T, Yoshikawa H, Kanda T. 2007. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Virology 358:266–272.

Matsumoto K, Yoshikawa H, Nakagawa S, Tang X, Yasugi T, Kawana K, Sekiya S, Hirai Y, Kukimoto I, Kanda T, Taketani Y. 2000. Enhanced oncogenicity of human papillomavirus type 16 (HPV16) variants in Japanese population. Cancer Lett 156:159–165.

Matsumoto K, Leggatt GR, Zhong J, Liu X, de Kluyver RL, Peters T, Fernando GJ, Liem A, Lambert PF, Frazer IH. 2004. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors. J Natl Cancer Inst 96: 1611–1619.

Matsumoto K, Yasugi T, Oki A, Fujii T, Nagata C, Sekiya S, Hoshiai H, Taketani Y, Kanda T, Kawana T, Yoshikawa H. 2006. IgG antibodies to HPV16, 52, 58 and 6 L1-capsids and spontaneous regression of cervical intraepithelial neoplasia. Cancer Lett 231:309–313.

Matsumoto K, Oki A, Furuta R, Maeda H, Yasugi T, Takatsuka N, Hirai Y, Mitsuhashi A, Fujii T, Iwasaka T, Yaegashi N, Watanabe Y, Nagai Y, Kitagawa T, Yoshikawa H, Japan HPV And Cervical Cancer (JHACC) Study Group. 2010. Tobacco smoking and regression of low-grade cervical abnormalities. Cancer Sci 101:2065–2073.

Matsumoto K, Oki A, Furuta R, Maeda H, Yasugi T, Takatsuka N, Mitsuhashi A, Fujii T, Hirai Y, Iwasaka T, Yaegashi N, Watanabe Y, Nagai Y, Kitagawa T, Yoshikawa H, for Japan HPV And Cervical Cancer (JHACC) Study Group. 2011. Predicting the progression of cervical precursor lesions by human papillomavirus genotyping: A prospective cohort study. Int J Cancer 128:2898–2910.

Mbulawa ZZ, Williamson AL, Stewart D, Passmore JA, Denny L, Allan B, Marais DJ. 2008. Association of serum and mucosal neutralizing antibodies to human papillomavirus type 16 (HPV-16) with HPV-16 infection and cervical disease. J Gen Virol 89:910–914.

Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. 1998. Natural history of cervical squamous intraepithelial lesions: A meta-analysis. Obstet Gynecol 92:727–735.

Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518–527.

Nagano H, Yoshikawa H, Kawana T, Yokota H, Taketani Y, Igarashi H, Yoshikura H, Iwamoto A. 1996. Association of multiple human papillomavirus types with vulvar neoplasias. J Obstet Gynaecol Res 22:1–8.

Ochi H, Kondo K, Matsumoto K, Oki A, Yasugi T, Furuta R, Hirai Y, Yoshikawa H, Kanda T. 2008. Neutralizing antibodies against human papillomavirus types 16, 18, 31, 52, and 58 in serum samples from women in Japan with low-grade cervical intraepithelial neoplasia. Clin Vaccine Immunol 15:1536–1540.

Östör AG. 1993. Natural history of cervical intraepithelial neoplasia: A critical review. Int J Gynecol Pathol 12:186–192.

Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, FitzGerald PC, Krüger Kjaer S, Lowy DR, Schiller JT. 2004. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321:205–216.

Safaeian M, Porras C, Schiffman M, Rodriguez AC, Wacholder S, Gonzalez P, Quint W, van Doorn LJ, Sherman ME, Xhenseval V, Herrero R, Hildesheim A, Costa Rican Vaccine Trial Group. 2010. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst 102:1653–1662.

Sasagawa T, Yamazaki H, Dong YZ, Satake S, Tateno M, Inoue M. 1998. Immunoglobulin-A and -G responses against virus-like particles (VLP) of human papillomavirus type 16 in women with cervical cancer and cervical intra-epithelial lesions. Int J Cancer 75:529–535.

Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T Jr, Young N, Forum Group Members; Bethesda 2001 Workshop. 2002. The 2001 Bethesda System: Terminology for reporting results of cervical cytology. JAMA 287:2114–2119.

Stanley M. 2010. Prophylactic human papillomavirus vaccines: Will they do their job? J Intern Med 267:251–259.

Wolkers MC, Brouwenstijn N, Bakker AH, Toebes M, Schumacher TN. 2004. Antigen bias in T cell cross-priming. Science 304: 1314–1317.

Yoshikawa H, Kawana T, Kitagawa K, Mizuno M, Yoshikura H, Iwamoto A. 1991. Detection and typing of multiple genital human papillomaviruses by DNA amplification with consensus primers. Jpn J Cancer Res 82:524–531.

ORIGINAL ARTICLE

A Possible Coagulation-Independent Mechanism for Pregnancy Loss Involving $\beta_2$glycoprotein 1-Dependent Antiphospholipid Antibodies and CD1d

Yuki Iwasawa[1], Kei Kawana[1], Tomoyuki Fujii[1], Danny J. Schust[2], Takeshi Nagamatsu[1], Yukiko Kawana[1], Seisuke Sayama[1], Shiho Miura[1], Junko Matsumoto[1], Katsuyuki Adachi[1], Hironobu Hyodo[1], Takahiro Yamashita[1], Shiro Kozuma[1], Yuji Taketani[1]

[1]Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, Tokyo, Japan;
[2]Division of Reproductive Endocrinology and Fertility, Department of Obstetrics, Gynecology and Women's Health, University of Missouri-Columbia School of Medicine, Columbia, MO, USA

Keywords
Antibody cross-linking, CD1d, phosphatidylserine, recurrent pregnancy loss, $\beta_2$glycoprotein1 (β2GP1) antibody

Correspondence
Kei Kawana, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
E-mail: kkawana-tky@umin.ac.jp

Submitted March 8, 2011;
accepted April 28, 2011.

Citation
Iwasawa Y, Kawana K, Fujii T, Schust DJ, Nagamatsu T, Kawana Y, Sayama S, Miura S, Matsumoto J, Adachi K, Hyodo H, Yamashita T, Kozuma S, Taketani Y. A possible coagulation-independent mechanism for pregnancy loss involving $\beta_2$glycoprotein 1-dependent antiphospholipid antibodies and CD1d. Am J Reprod Immunol 2012; 67: 54–65

doi:10.1111/j.1600-0897.2011.01028.x

Problem

$\beta_2$glycoprotein1 (β_2GP1)-dependent antiphospholipid antibodies (aPL) increase the risk for recurrent pregnancy loss. We address whether anti-β_2GP1 antibodies can interact with phosphatidylserine (PS)-bearing CD1d on trophoblast cells and induce local inflammation.

Methods

CD1d-bearing choriocarcinoma cells were used in flow cytometry and immunoprecipitation experiments. CD1d-mediated cytokine induction was assessed using antibody cross-linking. Cytokine production during co-culture of decidual lymphocytes with CD1d-bearing cells was also examined.

Results

Trophoblast surface-expressed CD1d forms a complex with PS-bound β_2GP1. Anti-β_2GP1 mAb cross-linking causes IL12p70 release from CD1d-bearing cells. IL12p70 release from CD1d-bearing trophoblast cells was also induced during co-culture with human decidual lymphocytes. The addition of anti-β2GP1 mAb to co-cultures resulted in a three-fold increase in IL12p70 secretion. IFNγ secretion from decidual lymphocytes was also induced during co-culture with anti-β2GP1 mAbs.

Conclusions

β_2GP1-dependent IL12 release from CD1d-bearing trophoblast in the presence of aPL may link the antiphospholipid syndrome to pregnancy loss via an inflammatory mechanism.

Introduction

Antiphospholipid syndrome (APS) is characterized by the production of autoantibodies against negatively charged membrane phospholipid-dependent antigens, including cardiolipin and phosphatidylserine. APS is clinically associated with thrombocytopenia, thrombosis, and pregnancy loss.[1,2] The major target antigen for antiphospholipid antibodies (aPL) has recently been identified as β_2GP1. β_2GP1 molecule is present in the peripheral blood and can act as an inhibitor of the intrinsic coagulation cascade,[3] platelet aggregation, and the prothrombinase activity of activated platelets *in vitro*.[4,5] The role of anti-β2GP1 antibodies in APS-related pregnancy loss may involve interference with the activity of β2GP1 bound to phospholipids on

© 2011 John Wiley & Sons A/S

activated platelets and the induction of coagulation in the placenta.[6,7] This would suggest that anti-β2GP1 antibody-mediated pregnancy loss occurs after the establishment of blood flow through the placental vasculature (i.e. 9–10 weeks of gestation) and would exclude those anti-β2GP1 antibody-mediated losses known to occur during the first trimester. Examination of first-trimester decidua and trophoblast tissues from pregnancies complicated by the APS, however, has revealed little evidence of specific thrombotic placental pathology.[8] Pure thrombotic events cannot account for all the histopathologic findings in placentae from women with APS.[9]

CD1d is an MHC I-like molecule that presents self- or microbe-derived glycolipid rather than peptide antigens.[10] Its immune effectors are typically natural killer T (NKT) cells.[10] CD1d presents lipid antigens including bacterial and self-lipid. Phosphatidylserine (PS), phosphatidylethanolamin (PE) and phosphatidylinositol (PI) have been known to be presented by CD1d.[11] In humans, a specific subset of NKT cells expresses an invariant Vα24Jα18/Vβ11 T-cell receptor (iTCR) and can recognize CD1d on the surface of antigen-presenting cells (APCs) through this receptor. The activation of invariant NKT (iNKT) cells is antigen dependent, but the antigen itself can be derived from an invading microbe or possibly the host itself.[12] Recognition of CD1d by iNKT cells causes rapid release of IL4 and IFN-γ from the iNKT cell and thereby modulates the Th1/Th2 polarization of adaptive immune cells.[10] The function of CD1d can be addressed experimentally using monoclonal antibody (mAb) cross-linking of cell surface-expressed CD1d. CD1d cross-linking using an anti-CD1d mAb (51.1) induces tyrosine phosphorylation in the CD1d cytoplasmic tail, intracellular signaling through NF-κB and autocrine cytokine release from CD1d-bearing cells.[13,14] As CD1a does not have a tyrosine in its cytoplasmic tail, this cascade does not occur upon cross-linking of CD1a or chimeric molecules that include the CD1a cytoplasmic tail (e.g. CD1d/a, a chimera composed of the extracellular and transmembrane domains of CD1d and the cytoplamic tail of CD1a).[13]

Normal placental extravillous trophoblast cells (EVT) express the MHC class I-like molecule, CD1d, when analyzed by immunohistochemistry.[15] We have reported that CD1d is expressed on the surface of early extravillous trophoblast cells using transient primary cultures of cells isolated from normal placentae during early pregnancy.[16] We have also demonstrated that CD1d expression is regulated *in vivo* in a trophoblast differentiation-dependent manner. CD1d is strongly expressed in EVT located proximally in trophoblast cell columns.[17] Here, the proximity of EVT and iNKT cells would allow interaction of CD1d and its ligand during early placental formation, a process that requires a local pro-inflammatory milieu to promote invasion of EVT into the maternal decidua.[17] CD1d expression in EVT decreases in the distal trophoblast cell columns that invade into the decidua and differentiate into interstitial or endovascular trophoblast cells.[17] These distal EVT cells are closely opposed to a great number of decidual stromal cells and infiltrating decidual immune cells (including decidual iNKT cells). Both NKT cells in the decidua and the peripheral blood had an ability to rapidly produce cytokine associated with Th1 and Th2.[18] It has reported that the percentages of IL4 and IFNγ producing NKT cells were significantly increased in the decidua compared with the peripheral blood in pregnancy.[18] As massive activation of iNKT cells induces pregnancy loss [19,20] the activation of decidual iNKT cells must be tightly regulated. Decreased CD1d expression in distal cell columns may control global activation of iNKT cells. More detailed descriptions of human placental CD1d regulation and expression patterns have been difficult to obtain using stable culture system.

We hypothesized that some APS-associated pregnancy loss may be mediated by anti-β_2GP1 antibody-dependent inflammation at the maternal–fetal interface. We further implicate trophoblast-expressed CD1d molecules as integral to induction of this inflammation. In this work, we demonstrate that β_2GP1-dependent aPL promote IL12 release from CD1d-bearing extravillous trophoblast cell lines, and subsequent IFNγ production by decidual lymphocytes. This, in turn, could cause further activation of inflammatory cells, damage to trophoblast cells, and pregnancy loss.

Materials and methods

Cell Lines

Although we have reported a transient primary culture system for human trophoblast cells isolated from normal placenta during early pregnancy,[21] these cells are difficult to maintain in culture. We therefore used the well-described human trophoblast cell line, Jeg3, for the present studies. While Jeg3 cells are often used *in vitro* to represent extravillous

© 2011 John Wiley & Sons A/S

cytotrophoblast cells, they do not endogenously express CD1d, which is expressed only in proximal cell column EVT *in vivo*.[16] We therefore transduced CD1 genes into Jeg3 cells using a retroviral vector, pSR-neo, expressing CD1d or a CD1d/a chimeric molecule (kind gifts from Dr. R. S. Blumberg, Harvard Medical School, Boston, MA, USA).[13] Transduced cells were cultured in RPMI1640 (Invitrogen Corporations, Carlsbad, CA, USA) media supplemented with 10% FBS (Invitrogen Corporations) and 500 μg/mL of geneticin/neomycin (Invitrogen Corporations). Neomycin-resistant stable cell lines were established and named Jeg3/CD1d or Jeg3/CD1d/a cells. The chimeric molecule expressed in Jeg3/CD1d/a cells consisted of the extracellular and transmembrane components of CD1d fused to the cytoplasmic tail of CD1a.

Isolation and Culture of Human Decidual Lymphocytes

Human decidual iNKT cells were purified from human decidual tissue isolated after elective termination of uncomplicated first trimester pregnancies under the approval of the Ethical Committee of the Medical Faculty, University of Tokyo. Purified decidual iNKT cells were cultured as previously described.[22] Briefly, minced decidual tissues were digested with 10% collagenase (20 μL) and 20 U/mL DNase typeI (Invitrogen Corporations) in 10 mL RPMI 1640 containing 10%FBS and passed through mesh (100 μm pore size; Invitrogen Corporations). Cells were resuspended in PBS, layered over 5 mL of Ficoll (Sigma-Aldrich Inc., St. Louis, MO, USA) and centrifuged at $800 \times g$ for 20 min at room temperature. Cells at the interface between the PBS and Ficoll layers were collected, resuspended in RPMI1640 containing 10% FBS and 100 ng/mL of αGalCer and cultured at 37°C in 5% CO_2. An aliquot of the isolated lymphocytes was incubated with anti-Vα24-RPE or anti-Vβ11-FITC Abs (1 μg/mL) and analyzed by flow cytometry to confirm the presence of Vα24Vβ11 iNKT cells (data not shown).

In co-culture experiments, 10^5 αGalCer-stimulated decidual lymphocytes were incubated with 10^5 Jeg, Jeg/CD1d, or Jeg/CD1d/a cells at 37°C in 5% CO_2 for the times indicated. For experiments requiring exposure to anti-β2GP1 antibodies, anti-β2GP1 antibody or isotype-control antibodies were added to culture supernatants at a concentration of 10 μg/mL.

Flow Cytometry

Jeg3 cells were detached from culture plates with 0.05% EDTA in PBS and incubated with anti-CD1d (NOR3.2 Abcam Inc., Cambridge, MA, USA), anti-β_2GP1 (CHEMICON International, Temecula, CA, USA) or anti-PS (upstate (Millipore), Billerica, MA, USA) mAbs (1 μg/mL) in PBS for 30 min. For indirect staining experiments, cells were incubated with RPE anti-mouse IgG (Dako Cytomation, Glostrup, Denmark) for 30 min. Controls were exposed to an isotype-matched irrelevant mAb (1 μg/mL; Dako Cytomation). After washing, cells were subjected to flow cytometric analysis for RPE.

Immunoprecipitation and Western Immunoblotting

Cells were cultured in 10-cm plates in RPMI and used at near confluence. Equivalent aliquots of cell lysates were incubated overnight at 4°C with 10 μg/mL of anti-CD1d mAb or anti-AnnexinV Ab (BioVision, Mountain View, CA, USA) and 60 μL of Protein-G-Sepharose (GE Healthcare Bio-science, Piscataway, NJ, USA). As PS cannot be detected by Western blotting, these immunoprecipitants were immunoblotted with a mAb to Annexin V, a protein known to bind tightly to PS.[23] Precipitated proteins were separated across 10% polyacrylamide gels and transferred to polyvinylidene difluoride membranes. β_2GP1 levels were determined by Western immunoblotting (ECL advance Western blotting detection kit; GE Healthcare Bio-science, Piscataway, NJ, USA). The expression of β_2GP1 was detected using an anti-β_2GP1 mAb labeled with HRP (Peroxidase Labeling Kit; Roche Diagnostics, Lewes, UK).

CD1d Cross-Linking

Jeg3, Jeg3/CD1d, or Jeg3/CD1d/a cells were cultured in 12-well plates in RPMI and used at 80% confluence. Monolayer cells were exposed to ten [10] μg/ml of anti-CD1d (51.1; eBioscience, San Diego, CA, USA), anti-β_2GP1 (CHEMICON International) or isotype control (DakoCytomation) mAbs and incubated for 1 hr at 37°C. This anti-β_2GP1 antibody is non-functional and binds to two molecules of β_2GP1. Cells were washed with PBS and exposed to 10 μg/mL goat anti-mouse Ig antibody (CHEMICON International) as a cross-linker for 30 min at 37°C. Cells used in the anti-β_2GP1 mAb experiments were

© 2011 John Wiley & Sons A/S

not exposed to a secondary antibody. Cells were then washed three times and incubated in the serum-free growth media without antibiotics for periods of 0, 18, or 24 hr prior to use for RT-PCR or ELISA.

Quantitative RT-PCR

Quantitative IL12 p40 RT-PCR was performed in cultured Jeg3 cells after cross-linking. Total RNA was isolated (RNeasy; Qiagen Inc., Valencia, CA, USA) and 2 μg of total RNA were subjected to reverse transcription (ReverTraAce; TOYOBO, Tsuruga, Japan) according to the manufacturer's instructions. A volume of 0.2–2 μL of each RT-reaction was used for quantitative PCR (Light Cycler system; Roche Diagnostics, Lewes, UK) using the following primer pairs: IL12 p40-forward 5′-GGTCACACTGGA CCAAAGGGACTATG-3′, -reverse 5′- ATTCTGCTGCC GTGCTTCCAAC-3′[24]; and β-actin-forward 5′- GA-AATCGTGCGTGACATTAAGG-3′, -reverse 5′- TCAG GCAGCTCGTAGCTTCT C-3′.[25] β-actin mRNA levels were quantified in each sample as an internal control for normalization. RT-quantitative PCR experiments were repeated at least three times.

ELISA for IL12 and IFNγ

Culture media was collected at 0, 18, and 24 hr after cross-linking ($n = 4$) and levels of secreted IL12 p70 or IFNγ were quantified using solid phase sandwich ELISAs (R&D Systems). A standard curve was produced using absorbance measurements at 450 nm for standard samples. Each unknown sample was similarly measured and plotted using this standard curve. IL12 and IFNγ secretion levels in the presence of the anti-β2GP1 antibody were normalized by those in the absence of the antibody and indicated as ratios.

Statistical Analysis

Quantitative PCR and ELISA data are presented as means ± standard deviations. All experiments were performed independently three times. mRNA or cytokine secretion levels were compared between cell lines and among time points using Mann–Whitney analyses. A P-value of <0.05 was considered significant.

Results

Cell-Surface Expression of PS and β_2GP1 Bound to CD1d

CD1d is an MHC-like glycoprotein that presents lipid antigens derived from pathogens and from self, the latter including phosphatidylserine (PS).[11] Phosphatidylserine can associate with β2GP1 at the surface of trophoblast cells.[26,27] The carrier involved in intracellular trafficking and transport of PS-β2GP1 complexes to the cell surface has not been identified. We hypothesized that the PS-β2GP1 complex is presented by CD1d in trophoblast cells. To test our hypothesis, we developed a trophoblast cell model that remained undifferentiated with prolonged *in vitro* culture, but stably expressed CD1d at the cell surface. Jeg3 cells are a commonly used model for extravillous trophoblast cells, but these cells do not endogenously express CD1d (Fig. 1a, green line). We transduced CD1d into Jeg3 cells using a retroviral expression system to establish the stable Jeg3/CD1d cell line with strong cell surface expression of CD1d (Fig. 1b, green line). Jeg3 and Jeg3/CD1d cells were triple-stained for PS, β2GP1, and CD1d and analyzed by flow cytometry (Fig. 1). Both PS (red lines) and β2GP1 (blue lines) were expressed on the cell surface of Jeg3/CD1d with signal peaks that overlapped that of CD1d (green lines). Neither PS nor β2GP1 was expressed on the cell surface of Jeg3 that lacked CD1d.

Using similar methodologies, we generated a cell line expressing a chimeric CD1 molecule comprised of the extracellular domains of CD1d and intracellular domain of CD1a (CD1d/a). As CD1a lacks a tyrosine in its cytoplasmic tail, downstream tyrosine-based signaling does not occur upon ligand binding to chimeric surface CD1d/a molecules.[13] The resultant cell line, called Jeg3/CD1d/a cells, can be used as a dominant-negative control in CD1d cross-linking experiments. As with Jeg3/CD1d cells, PS and β2GP1 were expressed on the surface of Jeg3/CD1d/a cells (Fig. 1c). Flow cytometry patterns for PS and β2GP1 are nearly identical in Jeg3/CD1d and Jeg3/CD1d/a cells, suggesting that PS and β2GP1 may form a complex at the cell surface and indicating that cell surface expression of PS and β2GP1 depends on the presence of the extracellular domains of CD1d.

To address biochemical interactions between CD1d and the PS-β2GP1 complex, an anti-CD1d mAb was

© 2011 John Wiley & Sons A/S



Fig. 1 Cell-surface expression of PS and β_2GP1 is CD1d-dependent. Jeg3 (a), Jeg3/CD1d (b) and Jeg3/CD1d/a (c) cells were triple stained with the anti-CD1d mAb (green), the anti-PS Ab (red) and anti-β2GP1 mAb (blue) and analyzed using flow cytometry. Background staining with isotype-matched control antibody is also shown (black). Histograms are representative of at least four separate experiments. (Blue lines (β2GP1) merged red lines (PS) in each panel of Fig. 1 because of the co-localization of the two molecules).

used to co-precipitate CD1d and its associated molecules from total cell lysates of Jeg3 and Jeg3/CD1d cells. These immunoprecipitants were then immunoblotted to detect β2GP1 (Fig. 2a). A 42-KDa band representing β2GP1 was present only in the Jeg3/CD1d cells, although immunoglobulin heavy chains were detected in all cells. Interaction between Cd1d and PS was similarly verified using co-immuno-



Fig. 2 The PS-β_2GP1 complex binds to CD1d. An anti-CD1d mAb was used to immunoprecipitate CD1d from Jeg3 or Jeg3/CD1d total cell lysates. (a) Immunoprecipitants were immunoblotted with an HRP-labeled anti-β_2GP1 mAb to detect β2GP1. An extra-band at 42 KDa, representing β_2GP1, was observed only in the Jeg3/CD1d lane although bands representing immunoglobulin heavy chains were noted in both lanes. (b) The immunoprecipitants were immunoblotted with an anti-Annexin V mAb to detect Annexin V, a PS-binding protein. An extra-band at 35 KDa, representing annexin V, was observed only in the Jeg3/CD1d lane although bands representing immunoglobulin light chains were noted in both lanes.

precipitation and Western blotting. Again, primary immunoprecipitations used an anti-CD1d mAb. As PS cannot be detected by Western blotting, these immunoprecipitants were immunoblotted with a mAb to Annexin V, a protein known to bind tightly to PS[23] (Fig. 2b). Although we could not detect PS directly, these biochemical data suggested the hypothesis that the PS-β2GP1 complex is expressed on the trophoblast cell surface and is bound to CD1d.

Ligation of Cell Surface CD1d Promotes IL12 Release from Trophoblast Cells

Ligation of surface-expressed CD1d promotes rapid but transient cytokine secretion from CD1d-bearing cells.[13,28,29] Such ligation can also occur upon interaction with iTCR-expressing iNKT cells and via antibody cross-linking of CD1d.[28] The cytoplasmic tail of CD1d, but not CD1a, bears a target domain for potential tyrosine kinase activity characterized by the tyrosine endocytic sorting motif (YXXZ).[13] CD1d ligation induces tyrosine phosphorylation in its cytoplasmic tail, subsequent intracellular signaling, and autocrine cytokine release from CD1d-bearing cells.[14,28] The 51.1 anti-CD1d mAb is often used for CD1d cross-linking and its use creates an *in vitro* model for CD1d ligation.[13,14] We have reported that cross-linking of CD1d using 51.1, when combined with secondary anti-Ig antibodies, promotes IL12 and IL15 secretion from reproductive tract epithelial

© 2011 John Wiley & Sons A/S

cells.[29] Other groups have shown that similar CD1d cross-linking in monocytes and dendritic cells induces IL12 production [28] and IL12 is a known secretion product of normal human trophoblast cells.[30]

To address the function of CD1d in trophoblast cells, we examined CD1d ligation-induced autocrine cytokine production from Jeg3/CD1d cells. Jeg3 cells expressing the chimeric CD1d/a (Jeg3/CD1d/a cells) were used as dominant-negative control, as chimeric CD1d/a (extracellular CD1d and cytoplasmic CD1a) bears no target motif for phosphorylation. Both cell lines were first exposed to an anti-CD1d 51.1 mAb or to an isotype-control mAb. This was followed by exposure to a secondary anti-mouse IgG antibody cross-linker. The cells were then examined for IL-12 transcription (Fig. 3) using RT-PCR. Transcription of IL12 (p40) increased relatively rapidly (18 hr after cross-linking) in Jeg3/CD1d cells exposed to the CD1d-specific 51.1 mAb but did not increase in those exposed to isotype-control antibody. Although Jeg3/CD1d/a cells express cell-surface CD1d (shown in Fig. 1c), IL12 production was not induced in these cells upon exposure to anti-CD1d mAb or isotype control antibodies, indicating that IL12 production is mediated through pathways involving the cytoplasmic tail of CD1d.



Fig. 3 CD1d cross-linking using anti-CD1d primary and anti-Ig secondary antibodies induces IL12 transcription from Jeg3/CD1d cells but not Jeg3/CD1d/a cells. Jeg3/CD1d cells or Jeg3/CD1d/a were exposed in culture to 10 μg/mL of the anti-CD1d mAb (51.1) or an isotype-control mAb for 1 hr. After washing, 10 μg/mL of goat anti-mouse Ig antibody was added as a cross-linker for 30 min to all cells. Cells were harvested at 0, 18, and 24 hrs after secondary antibody cross-linking. IL-12 (p40) mRNA levels were analyzed using quantitative RT-PCR and normalized to β-actin. Mean mRNA levels and standard deviations were plotted against time. Asterisks indicate those time point comparisons with statistical significance within a cell-line exposure ($P < 0.05$; $n = 4$).

An anti-β2GP1 Monoclonal Antibody Induces Autocrine IL12 Production from Trophoblast Cells by CD1d Ligation in the Absence of a Secondary Cross-Linker

Existing *in vitro* models for antibody cross-linking of CD1d requires use of primary and secondary antibodies.[13,28,29] Several investigators have demonstrated that one anti-β2GP1 antibody binds two cell-surface β2GP1 molecules.[31] In light of our finding that β2GP1 appears to be bound to cell-surface CD1d molecules via PS, we hypothesized that a single anti-β2GP1 antibody might ligate two CD1d molecules via their bound PS-β2GP1 complexes. This CD1d ligation would not require use of secondary antibodies and thereby could commonly occur *in vivo*. To address this hypothesis, Jeg3/CD1d and Jeg3/CD1d/a cells were exposed to anti-β2GP1 mAbs in the absence of secondary cross-linking antibodies. Post-exposure RT-PCR revealed that transcription of IL12 (p40) increased in Jeg3/CD1d cells 18 and 24 hr after exposure to anti-β2GP1 mAb alone (Fig. 4). Jeg3/CD1d cells exposed to isotype control and Jeg3/CD1d/a cells exposed to the anti-β2GP1 mAb exhibited no change in IL12 transcription when analyzed up to 24 hr post-exposure. Notably, the increase in IL12 transcription after anti-β2GP1 mAb exposure was greater than that seen after combined anti-CD1d and secondary antibody exposure (Fig. 3).

Autocrine Secretion of IL12 from CD1d-Bearing Trophoblast Cells upon CD1d Ligation

To examine autocrine IL12 production from CD1d-bearing JEG3 cells after CD1d ligation, protein secretion into the culture media was assessed by ELISA (Fig. 5). Jeg3, Jeg3/CD1d, or Jeg3/CD1d/a cells were exposed to an anti-CD1d mAb (51.1) then to secondary antibody cross-linker as described previously. In separated cultures, these same cells were also

© 2011 John Wiley & Sons A/S



Fig. 4 Ligation of CD1d/PS/β_2GP1 complexes on Jeg3/CD1d cells using only anti-β_2GP1 mAbs increases IL12 transcription. Anti-β2GP1 and isotype-matched control mAbs were used as cross-linking antibodies in the absence of a secondary cross-linking reagent. Cells were harvested at 0, 18, and 24 hrs after cross-linking. IL-12 (p40) mRNA levels were analyzed using quantitative RT-PCR and normalized to β-actin. Mean mRNA levels and standard deviations were plotted against time. Asterisks indicate those time point comparisons with statistical significance within a cell-line exposure ($P < 0.05$; $n = 4$).



Fig. 5 Ligation of CD1d on Jeg3/CD1d cells using either anti-CD1d or anti-β_2GP1 mAbs increases IL12 secretion from Jeg3/CD1d cells. After cross-linking by anti-CD1d or anti-β_2GP1 mAb as shown in Fig. 4, cells were incubated in serum-free growth media without antibiotics for periods of 0–24 hrs. Autocrine IL12 secretion from trophoblast cell lines at each time point was assessed by ELISA for IL-12 (p70). Mean values with standard deviations are presented. Asterisks indicate those comparisons (before versus after cross-linking and among time points) with statistical significance ($P < 0.05$; $n = 4$).

exposed to an anti-β2GP1 mAb in the absence of a cross-linker. IL12 secretion increased in Jeg3/CD1d cells in both conditions, but neither exposure affected IL12 secretion in Jeg3/CD1d/a cells. IL12 secretion peaked at 18 hr after both anti-CD1d/secondary antibody and anti-β2GP1 cross-linking in Jeg3/Cd1d cells. Peak IL12 secretion levels were approximately three-fold higher than baseline levels after anti-β2GP1 mAbs cross-linking. The increase in IL12 secretion was higher after exposure to anti-β2GP1 mAbs alone when compared with combined anti-CD1d mAb/secondary antibody exposure, although the difference was of marginal significance ($P = 0.055$). These results again support the hypothesis that the induction of IL12 production requires CD1d-mediated intracellular signaling.

IL12 Production from CD1d-Bearing Trophoblast Cells upon Co-Culture with Normal Human Decidual Lymphocytes

It is reported that the percentages of NKT cells were significantly increased in the decidua compared with the peripheral blood.[18] Boyson et al.[19] has reported that CD1d-restricted $V\alpha24^+V\beta11^+$ iNKT cells comprise 0.48% of $CD3^+$ lymphocytes isolated from human decidual tissues at 7–9 gestational weeks. This is much higher than the 0.04% frequency in peripheral blood. To better mimic occurrences at the human maternal–fetal interface in normal pregnancies, we developed an *in vitro* model that exposed CD1d-bearing trophoblast-derived cells to decidual lymphocytes from normal human pregnancies at 7–9 weeks of gestation. Decidual lymphocytes were stimulated with αGalCer, a specific ligand for iTCR, to increase the proportion of $V\alpha24^+$ $V\beta11^+$ iNKT cells prior to co-culture with Jeg3 or Jeg3/CD1d cells. The proportion of the iNKT cells increased from 0.4–0.5 to 7–8% of decidual lymphocytes after αGalCer stimulation, but did not differ by the gestational age of the pregnancy from which the lymphocytes were isolated (data not shown). Jeg3 or Jeg3/CD1d cells were then cultured with or without decidual lymphocytes derived from pregnancies at either 7 or 9 gestational weeks; lymphocytes from a single pregnancy were used for all exposures within a single experiment. Decidual lymphocytes from the same pregnancy were cultured alone as an internal control (Figs 6–8). Secretion of IL12 increased 18 hrs after exposure of Jeg3/CD1d cells to decidual lymphocytes in co-culture, while neither co-culture of decidual

© 2011 John Wiley & Sons A/S



Fig. 6 IL12 secretion from Jeg3/CD1d cells is induced by the presence of decidual lymphocytes that include CD1d-restricted iNKT cells. Decidual lymphocytes were isolated from normal human decidual tissues collected at 7–9 gestational weeks. 10^5 decidual lymphocytes were cultured with Jeg3 or Jeg3/CD1d cells. Jeg3/CD1d cells alone and decidual lymphocytes alone were also cultured as controls. Autocrine IL12 secretion from trophoblast cells at the 18 hrs time point was assessed by ELISA for IL-12 (p70). Mean values with standard deviations are presented. Asterisks indicate those comparisons with statistical significance ($P < 0.05$; $n = 4$).



Fig. 7 Anti-β_2GP1 mAb enhances IL12 secretion during co-culture of Jeg3/CD1d cells and decidual lymphocytes. Decidual lymphocytes were co-cultured with Jeg3, Jeg3/CD1d, or Jeg3/CD1d/a cells. Decidual lymphocytes were also cultured alone as an internal control. Cultured cells were exposed to anti-β_2GP1 or control mAbs for 24 hrs (10 μg/mL). IL12 p70 levels in medium collected from each culture at each time point was measured by ELISA. The ratio of IL12 production after anti-β_2GP1 and control mAbs exposure is depicted (anti-β_2GP1/control mAb). Mean values with standard deviations are presented. Asterisks indicate those comparisons with statistically significant differences ($P < 0.05$; $n = 4$).

lymphocytes alone, Jeg3 cells and decidual lymphocytes nor of Jeg3/CD1d cells alone induced IL12 production (Fig. 6). This *in vitro* model recapitulates physiological interactions between CD1d-bearing trophoblast cells and decidual lymphocytes at the maternal–fetal interface in the absence of antibody-mediated stimulation. The increases in IL12 production in this model were less than those seen in antibody-cross-linking experiments that modeled pathological conditions.

Anti-β2GP1 mAbs Enhance Cytokine Induction by CD1d-Bearing Trophoblast in Co-Culture with Decidual Lymphocytes

Autocrine IL12 secretion from CD1d-bearing trophoblast cells was next induced by either antibody cross-linking or interaction with decidual lymphocytes, including CD1d-restricted iNKT cells. Here, we attempted to mimic the microenvironment at the maternal–fetal interface when pathologic anti-β2GP1 mAbs are present (Figs 7 and 8). Decidual lymphocytes derived from normal 7–9 week pregnancies were co-cultured alone, with Jeg3, Jeg3/CD1d, or Jeg3/CD1d/a cells in the presence of anti-β2GP1 or control mAbs. IL12 secretion levels in co-culture media were first measured by ELISA to assess the response of trophoblast cells to anti-β2GP1 and expressed as a ratio of anti-β2GP1 mAb exposure: control mAb exposure to reveal specific effect of anti-β2GP1 mAbs (Fig. 7). A statistically significant, 3-fold increase in IL12 production ratios were noted 18 hrs after mAb exposure in Jeg3/CD1d cells. IL12 secretion ratios were also significantly increased in Jeg3/CD1d cells when compared with Jeg3 and Jeg3/CD1d/a cells. Cultures containing lymphocytes alone, lymphocytes with Jeg3, and lymphocytes with

© 2011 John Wiley & Sons A/S



Fig. 8 Anti-β_2GP1 mAb enhances IFNγ secretion when added to co-cultures containing Jeg3/CD1d cells and decidual lymphocytes. IFNγ production in culture media collected for Fig. 7 was measured by ELISA and the production of IFNγ expressed as a ratio of anti-β_2GP1-exposed over control mAb-exposed specimens (anti-β_2GP1/control mAb). Mean values with standard deviations are presented. Asterisks indicate those comparisons with statistically significant differences ($P < 0.05$; $n = 4$).

Jeg3/CD1d/a cells did not show significant alterations in IL12 production ratios. These results indicate that anti-β2GP1 mAbs enhance the CD1d-dependent IL12 production stimulated by decidual lymphocyte co-culture. They also suggest that anti-β2GP1 antibody can ligate two CD1d molecules via their attached PS-β2GP1 complexes even in the presence of background stimulation by CD1d-restricted iNKT cells.

We also used methodology similar to that which generated Fig. 7 to examine the secretion of IFNγ into co-culture media in the presence of anti-β2GP1 or control mAbs (Fig. 8). Unlike IL12, there was a trend toward increased IFNγ secretion 18 hrs after antibody exposure in all cultures. A statistically significant increase, however, was only demonstrated in co-cultures of Jeg3/CD1d cells with decidual lymphocytes. These data show that the presence of anti-β2GP1 mAbs may enhance IFNγ release in a maternal–fetal microenvironment interface in which CD1d-bearing trophoblast cells contact decidual lymphocytes.

Discussion

Despite the long-held belief that aPL-related pregnancy loss results from aberrant placental coagulation, direct examination of placental and first-trimester decidual tissues from pregnancies complicated by the antiphospholipid syndrome reveal little evidence for thrombotic placental pathology.[8] This suggests that aPL can induce pregnancy failure through alternative mechanisms. Recently, specific aPLs, called anti-β2GP1 antibodies, have been shown to directly alter trophoblast cell maturation,[8,32] giant multinuclear cell formation and invasion by EVT [24,32] and human chorionic gonadotropin secretion by syncytiotrophoblast.[11] Nakashima et al.[33] reported a possible miscarriage mechanism by which activated maternal NK cells attack the EVT and induce EVT apoptosis.

CD1d is expressed on the surface of APCs, including: dendritic cells, macrophages, B cells, and epithelial cells. Lipid antigens, derived from invading microbes or host phospholipid, are presented by CD1d to CD1d-restricted iNKT cells. In normal pregnancy, interactions between CD1d and iNKT cells activate iNKT cells and induce the release of pro-inflammatory cytokines, such as IL12, from CD1d-bearing cells.[28] IL12, in turn, induces IFNγ-producing NK, NKT, T helper and cytotoxic T-cell activity, thereby initiating a potent local inflammatory cascade. IFNγ also upregulates CD1d expression on APCs in a paracrine fashion (Fig. 9, upper panel). Several studies, including ours, have demonstrated CD1d expression in EVT isolated from early gestation human placentas.[15,19,34] Appropriate placental formation involves appropriate invasion of fetally derived EVT into the maternal decidua, a process that appears to require a localized, transient and tightly controlled pro-inflammatory reaction.[17] At the human maternal–fetal interface, CD1d-bearing EVT contact maternal iNKT cells during early placental formation. Our data demonstrate a relatively weak, but significant increase in IL12 protein levels in the media of Jeg3/CD1d and human decidual lymphocyte co-cultures in the absence of anti-β2GP1 mAbs (Fig. 6). This suggests that appropriate IL12 secretion secondary to physiologic interactions of CD1d and iNKT cells at the human maternal–fetal interface should be at relatively low levels.

Maternal antibodies are present in the spiral arteries, in the decidua and in the maternal blood bathing the placental villi. Therefore, maternal aPL have

© 2011 John Wiley & Sons A/S